Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses challenges faced jointly by the US and EU biosimilars markets.
Transcript:
I think that's the very large question, of course, but maybe let me sum up. According to our US colleagues, when I look at the United States, of course the biggest, key challenge is definitely the famous “patent thickets” linked with all the patent litigation. And the misinformation [and] scaremongering. I think scaremongering is very dangerous. When patients get information, it’s difficult to let go.
Those are very important things; even in the European Union where we have been dealing with biosimilars since 2006, we still need to continue to educate and inform. I think that’s crucial and we cannot give up on that. It has to be permanent access to information and new ways of explaining, so that’s very important.
Also, according to our US colleagues, we really need strong incentives for the United States, and incentives which are across the different stakeholder groups, and then uptake measures in order that somehow, one day, the biosimilar market takes off in the United States.
Of course, it is very complex, but maybe these are the key elements there; those who are familiar with the US environment know what I’m referring to.
With regard to the European Union, as you well know, I think we have a lot of experience. Maybe we have today with the EU approved biosimilars maybe 800 million patient days or even 900 million patient days experience. So biosimilars are accepted. They are accepted as being safe and efficacious alternative treatments.
We also have very good experience with switching. It is regarded as safe. The medical societies and medical communities are endorsing that publicly more and more.
Nevertheless, again, education has to continue. It’s never finished. There are new molecules coming out, new biosimilars, there are new treatment areas where biosimilars are first. When the first cancer biosimilar monoclonals were approved, we had to start again in those communities. It’s a never-ending approach; it’s very important.
Certainly now the key challenge for the European Union is that [while] biosimilars are broadly accepted, we need to now strike a balance between, I would say, short-term cost savings and then long-term sustainability for this industry.
It is of course very complex, but that’s what we have to look at because, I think, that’s also valid for the United States. We have to have policies in place which assure long-term sustainability for this industry. Otherwise, they will not further invest into biosimilar development.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
2 Clarke Drive
Cranbury, NJ 08512